ClinicalTrials.Veeva

Menu

International Rare Brain Tumor Registry (IRBTR)

Children's National logo

Children's National

Status

Enrolling

Conditions

BCOR ITD Sarcoma
Unclassified Tumor, Malignant
CNS Sarcoma
Astroblastoma

Study type

Observational

Funder types

Other

Identifiers

NCT05697874
STUDY00000324

Details and patient eligibility

About

The objective of the International Rare Brain Tumor Registry (IRBTR) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed with rare brain tumors.

Full description

The International Rare Brain Tumor Registry (IRBTR) is a prospective observational study that will collect tumor samples and matched clinical and radiological data to better understand the outcomes of patients with rare brain tumors in particular: CNS sarcoma, BCOR, MN-1 altered tumors, PLAG/L1, and other rare or unclassified rare brain tumors.

Data collected include demographics, disease characteristics, treatment information, radiological imaging, and biospecimen collection if available ( tumor tissues Patients will be followed longitudinally to obtain outcome data. Data collection will continue for approximately 10 years.

Enrollment

5,800 estimated patients

Sex

All

Ages

Under 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with a known or suspected CNS Sarcoma.
  • Patients with a known or suspected BCOR-altered brain tumor
  • Patients with a known or suspected Astroblastoma/NM-1 altered brain tumor
  • Patients with known or suspected histologically ambiguous/unclassifiable brain tumor
  • Patients with a known or suspected rare brain tumor.
  • Signed informed consent by patient/ parent or guardian (assent where applicable) to participate in the study.

Exclusion criteria

  • The patient has an extra-CNS primary tumor.
  • The patient is older than 46 years of age at diagnosis.
  • The patient or family is not willing to participate or does not sign informed consent.

Trial design

5,800 participants in 5 patient groups

CNS Sarcoma
Description:
Patients diagnosed with Central nervous system (CNS) sarcomas
BCOR-altered
Description:
Patients diagnosed with tumors characterized by alterations in the BCOR gene.
Astroblastoma/MN-1- altered
Description:
Patients diagnosed with Astroblastomas/MN-1 alterations
Unclassifiable tumors
Description:
Patients diagnosed with histologically ambiguous tumors or tumors that fail to classify with the current diagnostic methods.
Other Rare Brain tumors
Description:
Patients diagnosed with other rare brain tumors that do not meet the criteria for cohorts 1-4.

Trial contacts and locations

4

Loading...

Central trial contact

Skyler Speciale, RN; Adriana Fonseca, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems